In March, GileadSciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.
and breast and bladder cancer therapy Trodelvy (from Immunomedics). GileadSciences's Economic Impact: An Analysis Market Capitalization Analysis: With a profound presence, the company's market ...